Literature DB >> 14716220

Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion.

Sabina Frascarelli1, Sandra Ghelardoni, Simonetta Ronca-Testoni, Riccardo Zucchi.   

Abstract

We investigated the effect of different ACE inhibitors on tissue injury in isolated rat hearts subjected to 30 minutes of ischemia followed by 120 minutes of reperfusion. Zofenoprilat (1-100 microM), but not enalaprilat or lisinopril, significantly reduced infarct size, as estimated on the basis of triphenyltetrazolium chloride staining. The protection was not reproduced by the angiotensin II receptor antagonist irbesartan, and it was partly abolished by the bradykinin receptor antagonist HOE 140. Zofenoprilat molecule contains a sulfhydryl group, and its administration, as compared with enalaprilat or lisinopril administration, was associated with better preservation of protein thiols at the end of ischemia. We conclude that zofenopril has a specific cardioprotective effect, which might be related either to interference with bradykinin metabolism or to preservation of protein sulfhydryl groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716220     DOI: 10.1097/00005344-200402000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Effect of acute and chronic zofenopril administration on cardiac gene expression.

Authors:  Vittoria Carnicelli; Sabina Frascarelli; Riccardo Zucchi
Journal:  Mol Cell Biochem       Date:  2011-03-11       Impact factor: 3.396

Review 2.  Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.

Authors:  Claudio Borghi; Arrigo F G Cicero
Journal:  Vasc Health Risk Manag       Date:  2006

3.  Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.

Authors:  Erminia Donnarumma; Murtuza J Ali; Amanda M Rushing; Amy L Scarborough; Jessica M Bradley; Chelsea L Organ; Kazi N Islam; David J Polhemus; Stefano Evangelista; Giuseppe Cirino; J Stephen Jenkins; Rajan A G Patel; David J Lefer; Traci T Goodchild
Journal:  J Am Heart Assoc       Date:  2016-07-05       Impact factor: 5.501

4.  Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.

Authors:  Claudio Borghi; Stefano Omboni; Salvatore Novo; Dragos Vinereanu; Giuseppe Ambrosio; Ettore Ambrosioni
Journal:  J Cardiovasc Pharmacol       Date:  2017-05       Impact factor: 3.105

5.  Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study.

Authors:  Claudio Borghi; Arrigo F G Cicero; Ettore Ambrosioni
Journal:  Vasc Health Risk Manag       Date:  2008

6.  Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry.

Authors:  Claudio Borghi; Stefano Omboni; Arrigo Fg Cicero; Stefano Bacchelli; Daniela Degli Esposti; Salvatore Novo; Dragos Vinereanu; Giuseppe Ambrosio; Ettore Ambrosioni
Journal:  Open Heart       Date:  2015-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.